Statins Lower HIV-1 Infection by Disrupting CCR5 and RANTES Levels
Author Information
Author(s): Nabatov Alexey A., Pollakis Georgios, Linnemann Thomas, Paxton William A., de Baar Michel P.
Primary Institution: Academic Medical Center of the University of Amsterdam
Hypothesis
Can statins reduce HIV-1 infection by modulating CCR5 and RANTES expression in CD4+ T lymphocytes?
Conclusion
Statins can reduce CCR5 expression and increase RANTES levels, leading to a preferential decrease in R5 HIV-1 infection.
Supporting Evidence
- Statins reduced CCR5 expression on CD4+ T lymphocytes.
- RANTES levels increased in statin-treated lymphocytes.
- Statins preferentially inhibited R5 HIV-1 infection over X4.
Takeaway
Statins, which are usually used to lower cholesterol, can also help fight HIV by changing how certain immune cells work.
Methodology
CD4+ T lymphocytes were treated with various statins and analyzed for CCR5 and RANTES expression levels and HIV-1 infection rates.
Limitations
The study was conducted in vitro, and results may not directly translate to in vivo conditions.
Participant Demographics
CD4+ T lymphocytes isolated from 5 separate individuals.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website